LabCorp Western Blot Policy: What Changed and Why It Matters
The LabCorp Western blot Lyme test policy change highlights a critical issue in Lyme disease diagnosis: access to testing and its limitations. :contentReference[oaicite:1]{index=1}
When LabCorp Restricted Western Blot Access
In 2014, LabCorp announced a policy change that sent shockwaves through the Lyme disease community: physicians would no longer be able to order Western blot testing unless the initial screening test (ELISA or IFA) was positive or equivocal.
If a screening test came back negative—even when clinical suspicion remained high—the Western blot was automatically denied.
For clinicians treating Lyme disease in endemic areas, this represented a major barrier to accurate diagnosis.
Why Physicians Ordered Western Blots Independently
Clinicians had strong reasons to order Western blot testing even when screening tests were negative.
Whole-cell ELISA sensitivity in patients with erythema migrans (EM rash) ranges from 33–49%. The FDA-approved C6 peptide test showed 37% sensitivity in well-defined cases and 66.5% in EM rash patients.
These numbers indicate that screening tests can miss a significant number of early Lyme cases.
Western blot testing provided additional diagnostic insight:
- IgM bands can persist for years after infection
- IgG bands may be positive even when screening tests are negative
For experienced clinicians, Western blot was often essential—not optional.
Why Testing Access Was Restricted
LabCorp’s decision reflected broader concerns in the diagnostic community:
Technical Complexity
Western blot requires visual interpretation, leading to variability between labs.
Surveillance vs Clinical Diagnosis
CDC two-tier criteria were designed for surveillance, not individual patient care.
Push for Standardization
Automated enzyme immunoassays offered faster, more standardized results.
Early Infection Limitations
Western blot may remain negative in the first weeks of infection.
These concerns favored standardization—but did not resolve clinical limitations.
The Impact on Patient Care
The restriction created immediate challenges:
- Delayed diagnosis
- Increased costs from alternative labs
- Limited access for high-suspicion patients
This exposed a core tension: policies built for standardization were being applied to complex individual cases.
What Changed: Current Access
LabCorp has since reversed its policy.
Physicians can now order Western blot testing regardless of screening results.
This reflects recognition that clinical decision-making requires flexibility.
Meanwhile, Modified Two-Tier Testing (MTTT) has emerged, using two enzyme immunoassays instead of Western blot.
However, Western blot remains valuable for its detailed antigen-specific information.
Why Testing Method Matters Less Than Clinical Judgment
All antibody-based tests share a limitation: they depend on immune response.
They cannot reliably address:
- Early infection (seronegativity)
- Immune suppression
- Antibiotic-altered responses
This means laboratory testing supports—but does not define—the diagnosis.
Clinical judgment remains essential.
Frequently Asked Questions
Can I order a Western blot through LabCorp now?
Yes. LabCorp reversed its 2014 restriction. Physicians can now order it regardless of screening results.
Why was Western blot restricted?
Due to concerns about variability, standardization, and adherence to two-tier testing protocols.
Is Western blot more accurate than ELISA?
It provides different information (band patterns), but both tests can miss early infection.
What is Modified Two-Tier Testing?
A newer approach using two immunoassays instead of ELISA + Western blot.
Which test should be used?
This depends on clinical judgment. No test replaces careful evaluation of symptoms and exposure history.
Clinical Takeaway
The LabCorp Western blot policy highlights a fundamental truth: access to testing matters—but testing limitations matter more.
Early Lyme disease—the stage when treatment is most effective—is precisely when testing is least reliable.
Restoring access to Western blot improved flexibility—but did not solve the underlying diagnostic challenge.
Lyme disease remains a clinical diagnosis supported by laboratory findings—not defined by them.
When symptoms and exposure suggest infection, care should not be delayed while waiting for tests to catch up with biology.
Related Reading
- Lyme Disease Testing and Diagnosis
- Understanding Lyme Disease Test Accuracy
- Beyond CDC Testing Guidelines
- Don’t Wait for a Positive Test
- Why I Treated Despite Negative Tests
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
